Alnylam Pharmaceuticals, Inc. (ALNY - Free Report) announced that it has submitted a marketing authorization application (“MAA”) to the European Medicines Agency (“EMA”), seeking approval of its investigational RNAi therapeutic, vutrisiran, for the treatment of adult patients with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis.
If approved in the European Union, vutrisiran might become a new, subcutaneously administered, once-quarterly treatment option for the given patient population.
Alnylam also plans to submit regulatory filings for vutrisiran in Brazil and Japan, later in 2021.
Shares of Alnylam have rallied 43% so far this year compared with the industry’s rise of 0.8%.
In June 2021, the FDA accepted the new drug application for vutrisiran to treat adult patients with polyneuropathy of hATTR amyloidosis. A decision from the regulatory body is expected on Apr 14, 2022.
Both the FDA and the EMA have granted Orphan Drug designation to vutrisiran for the treatment of ATTR amyloidosis.
We remind investors that Alnylam’s Onpattro is already approved for the treatment of polyneuropathy of hATTR amyloidosis. The injection recorded sales of $215.8 million in the first six months of 2021, up 62% year over year, driven by new patient demand.
Hence, the potential approval of vutrisiran should help Alnylam strengthen its portfolio and drive growth further in the days ahead.
Zacks Rank & Stocks to Consider
Alnylam currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the biotech sector include Spero Therapeutics, Inc. (SPRO - Free Report) , Vertex Pharmaceuticals Incorporated (VRTX - Free Report) and Corvus Pharmaceuticals, Inc. (CRVS - Free Report) , all carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Spero Therapeutics’ loss per share estimates have narrowed 8.2% for 2021 and 10.6% for 2022 over the past 60 days.
Vertex’s earnings estimates have been revised 10.2% upward for 2021 and 7.1% upward for 2022 over the past 60 days.
Corvus Pharmaceuticals’ loss per share estimates have narrowed 24.4% for 2021 and 21.4% for 2022 over the past 60 days.
Just Released: Zacks Top 10 Stocks for 2024
Hurry – you can still get in early on our 10 top tickers for 2024. Hand-picked by Zacks Director of Research, Sheraz Mian, this portfolio has been stunningly and consistently successful. From inception in 2012 through November, 2023, the Zacks Top 10 Stocks gained +974.1%, nearly TRIPLING the S&P 500’s +340.1%. Sheraz has combed through 4,400 companies covered by the Zacks Rank and handpicked the best 10 to buy and hold in 2024. You can still be among the first to see these just-released stocks with enormous potential.
See New Top 10 Stocks >>
Alnylam Pharmaceuticals, Inc. (ALNY - Free Report) announced that it has submitted a marketing authorization application (“MAA”) to the European Medicines Agency (“EMA”), seeking approval of its investigational RNAi therapeutic, vutrisiran, for the treatment of adult patients with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis.
If approved in the European Union, vutrisiran might become a new, subcutaneously administered, once-quarterly treatment option for the given patient population.
Alnylam also plans to submit regulatory filings for vutrisiran in Brazil and Japan, later in 2021.
Shares of Alnylam have rallied 43% so far this year compared with the industry’s rise of 0.8%.
In June 2021, the FDA accepted the new drug application for vutrisiran to treat adult patients with polyneuropathy of hATTR amyloidosis. A decision from the regulatory body is expected on Apr 14, 2022.
Both the FDA and the EMA have granted Orphan Drug designation to vutrisiran for the treatment of ATTR amyloidosis.
We remind investors that Alnylam’s Onpattro is already approved for the treatment of polyneuropathy of hATTR amyloidosis. The injection recorded sales of $215.8 million in the first six months of 2021, up 62% year over year, driven by new patient demand.
Hence, the potential approval of vutrisiran should help Alnylam strengthen its portfolio and drive growth further in the days ahead.
Zacks Rank & Stocks to Consider
Alnylam currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the biotech sector include Spero Therapeutics, Inc. (SPRO - Free Report) , Vertex Pharmaceuticals Incorporated (VRTX - Free Report) and Corvus Pharmaceuticals, Inc. (CRVS - Free Report) , all carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Spero Therapeutics’ loss per share estimates have narrowed 8.2% for 2021 and 10.6% for 2022 over the past 60 days.
Vertex’s earnings estimates have been revised 10.2% upward for 2021 and 7.1% upward for 2022 over the past 60 days.
Corvus Pharmaceuticals’ loss per share estimates have narrowed 24.4% for 2021 and 21.4% for 2022 over the past 60 days.
Just Released: Zacks Top 10 Stocks for 2024
Hurry – you can still get in early on our 10 top tickers for 2024. Hand-picked by Zacks Director of Research, Sheraz Mian, this portfolio has been stunningly and consistently successful. From inception in 2012 through November, 2023, the Zacks Top 10 Stocks gained +974.1%, nearly TRIPLING the S&P 500’s +340.1%. Sheraz has combed through 4,400 companies covered by the Zacks Rank and handpicked the best 10 to buy and hold in 2024. You can still be among the first to see these just-released stocks with enormous potential.
See New Top 10 Stocks >>
Get the latest research report on ALNY - FREE
Get the latest research report on VRTX - FREE
Get the latest research report on CRVS - FREE
Get the latest research report on SPRO - FREE